CMDBioscience announced today that they were named a "2011 company to watch" for the Cantor Colburn/ CCAT Innovation and Entrepreneurship Summit. The selection was from more than 100 start up and emerging companies that applied to present at the event which will take place on October 27th in New Haven, CT.
New Haven, CT September 8th , 2011: CMDBioscience announced today that they will present at the Roche Colorado Corporation Peptide Symposium 2011 in Boulder Colorado. The company will present recent case studies related to CMDInventusSM, their proprietary computational discovery platform aimed at discovering novel peptide candidates in the Peptide Technology Showcase.
New Haven, CT June 22nd, 2011: CMDBioscience announced today that they will exhibit at the 22nd American Peptide Symposium in San Diego, CA. The company will introduce CMDInventusSM, their proprietary computational discovery platform aimed at discovering novel peptide candidates.
CMDBioscience, a computational biotechnology company focused on developing computational tools to enable peptide discovery announced today the release of CMDInventus, a proprietary and fully validated computational peptide discovery platform. This platform when combined with the CMD expertise is poised to revolutionize the field of novel peptide discovery.
CMDBioscience, a CT based biotechnology company specializing in computer-aided peptide drug discovery, announced today the completion of a research collaboration aimed at identifying novel peptide antagonists of the dengue virus using the CMDBioscience proprietary computational peptide drug discovery platform.
Satisfied Users & 
Approved Press Releases
